Vigil Neuroscience announces the price of its initial public offering | Your money

CAMBRIDGE, Mass., Jan.6, 2022 (GLOBE NEWSWIRE) – Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today hui the price of its initial public offering of 7,000,000 common shares at a public price of $ 14.00 per share. All actions are offered by Vigil Neuroscience. The gross proceeds of the Offering, before deduction of sales rebates, subscription commissions and other offering fees payable by Vigil Neuroscience, are expected to be $ 98.0 million. In addition, the Underwriters have a 30-day option to purchase up to 1,050,000 additional Common Shares at the initial public offering price less rebates and underwriting commissions.

The shares are expected to begin trading on the Nasdaq Global Select Market on January 7, 2022 under the symbol “VIGL”. The offer is expected to close on January 11, 2022, subject to the satisfaction of customary closing conditions.

Morgan Stanley, Jefferies, Stifel and Guggenheim Securities act as co-book managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 6, 2022. The offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, New York, New York 10014 or by e-mail at; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by phone at 877-821-7388 or by email at Prospectus—; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by phone at 415-364-2720 or by email at; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by phone at (212) 518-9544 or by email at

This press release does not constitute an offer to sell or a solicitation of an offer to buy such securities, and there will be no sale of such securities in any state or jurisdiction where such an offer, solicitation or sale would be illegal before registration or qualification under the securities laws of that state or jurisdiction.

About Vigil Neuroscience

Vigil Neuroscience is a microglia-focused therapeutic company dedicated to developing treatments for rare and common neurodegenerative diseases by restoring alertness to microglia, the sentinel immune cells of the brain. We use the tools of modern neuroscientific drug development in multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families.

Caution regarding forward-looking statements

This press release includes certain disclosures that contain “forward-looking statements” including, without limitation, statements regarding Vigil Neuroscience’s expectations regarding the commencement of trading of its shares on the Nasdaq Global Select market, the completion and timing of the closing of the offer and the expected gross proceeds of the offer. Forward-looking statements are based on Vigil Neuroscience’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties associated with the satisfaction of customary closing conditions and the completion of the Offer, as well as the risks inherent in the development of biopharmaceuticals. and clinical trials. These and other risks and uncertainties are further described in the section entitled “Risk Factors” of the registration statement filed with the Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of this date, and Vigil Neuroscience assumes no obligation to update such information, except as required by applicable law. Readers should not trust any information on this page to be current or accurate after the date of publication.

Media Contact: Megan McGrath MacDougall Advisors Investor Contact: Christina Tartaglia Stern Investor Relations

Copyright 2022 GlobeNewswire, Inc.

About Barbara J. Ross

Check Also

Actelis Networks, Inc. Announces IPO Pricing

FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) — Actelis Networks, Inc. ASNS (“Actelis” or the …